LakeShore Biopharma Co., Ltd Stock Price, News & Analysis

LakeShore Biopharma (Nasdaq: LSB) announced its transition from Nasdaq to the OTC Pink Open Market effective September 22, 2025. The company's ordinary shares and warrants will trade under the new symbols "LSBCF" and "LSBWF" respectively.

The delisting from Nasdaq follows a determination letter received on September 11, 2025, citing non-compliance with the minimum bid price requirement and ineligibility for a compliance period due to a previous reverse stock split. Despite the market transition, LakeShore Biopharma maintains its SEC reporting status and business operations remain unchanged.

LakeShore Biopharma (Nasdaq: LSB) has received a delisting determination letter from Nasdaq on September 11, 2025, due to non-compliance with the minimum bid price requirement of $1.00 per share. The company is not eligible for the standard 180-day compliance period because it completed a 10-for-1 reverse stock split on October 1, 2024.

Unless LSB appeals by September 18, 2025, trading of its securities will be suspended on September 22, 2025. The company can request a hearing before the Nasdaq Hearings Panel, which would temporarily stay the suspension pending the Panel's decision. LakeShore is currently evaluating its options but cannot guarantee a successful appeal or ability to regain compliance.

LakeShore Biopharma (NASDAQ: LSB), a global biopharmaceutical company, has announced key developments in evaluating a non-binding proposal received on August 26, 2025. The company's independent special committee has appointed Kroll, LLC as financial advisor, along with Gibson, Dunn & Crutcher LLP as U.S. legal counsel and Maples and Calder as Cayman Islands legal counsel.

The Special Committee continues to evaluate the proposal, with no decisions made yet. The company emphasized there is no guarantee of a definitive offer, agreement execution, or transaction approval.

LakeShore Biopharma (NASDAQ:LSB) has received a revised preliminary non-binding proposal from a consortium led by Oceanpine Capital to acquire all outstanding shares not currently owned by the consortium for $0.86 per share in cash. The consortium, which currently owns 52.1% of LSB's outstanding shares, has formed an agreement to vote in favor of the proposed transaction and won't sell their shares or support competing bids.

In response, LSB's Board has formed a special committee of three independent directors, chaired by Adam Zhao, to evaluate the proposal. The company emphasizes that no decisions have been made regarding the proposal, and there's no guarantee of a definitive offer or transaction completion.

LakeShore Biopharma (NASDAQ:LSB), a global biopharmaceutical company, has received a preliminary non-binding acquisition proposal from Oceanpine Capital. The proposed all-cash transaction offers $0.86 per ordinary share for shares not currently owned by Oceanpine Capital.

The offer represents a 10.3% premium to LSB's last closing price on August 15, 2025, and an 11.4% premium to the 15-day average closing price. Oceanpine Capital plans to finance the transaction through rollover equity and available cash, with no financing condition attached. The company has engaged White & Case LLP as its international legal advisor.

LakeShore's Board of Directors will review and evaluate the proposal to determine the best course of action for the company and its shareholders. No decisions have been made regarding the company's response to the proposal.

LakeShore Biopharma (NASDAQ:LSB) reported its FY2025 financial results, showing mixed performance with improvements in profitability despite missing guidance targets. Total revenue increased 7.2% to RMB615.0 million, while gross profit rose 11.3% to RMB507.2 million with improved margins of 82.5%.

The company significantly narrowed its net loss to RMB100.0 million from RMB433.5 million in FY2024, while operating expenses decreased by 34.2%. Their flagship product, YSJATM rabies vaccine, has been administered in approximately 110 million doses and distributed to 1,911 county-level CDCs in China. The company is advancing a Phase III trial for a simplified four-dose regimen, targeting market approval by Q4 2026.

For FY2026, LSB projects revenue between RMB550-650 million, while facing challenges including intensified competition, pricing pressures, and ongoing litigation with their former Chairman affecting credit access.

LakeShore Biopharma (NASDAQ:LSB), a global biopharmaceutical company focused on vaccines and therapeutic biologics, has announced a US$15 million private placement financing agreement with an institutional investor.

The deal includes the issuance of 16,987,542 ordinary shares at US$0.883 per share, along with an equal number of warrants. Each warrant allows the purchase of one ordinary share at US$1.079 during a 36-month period. The private placement, exempt from registration under Regulation S, is expected to close upon meeting customary conditions.

LakeShore Biopharma (Nasdaq: LSB) has launched a novel packaging solution for its YSJA™ rabies vaccine (Vero cell) following regulatory approval on April 15, 2025. The innovative packaging features needle-free reconstitution technology, addressing key safety challenges in vaccine administration.

The new design includes specialized components for automatic clamping, needle-free reconstitution, and new needle injection, enhancing vaccination safety and convenience. Key benefits include:

• Reduced risk of compounding contamination
• Lower occupational exposure for medical staff
• Decreased needle tip pain
• Minimized particle pollution and inflammation risk

This marks the first commercial application of advanced liquid transfer device technology in China's rabies vaccine market, with nationwide distribution set to begin within weeks of the April 18, 2025 launch meeting in Changsha, Hunan Province.

LakeShore Biopharma (LSB) reported strong financial results for H1 FY2025, achieving total revenue of RMB 371.9 million, up 36.2% YoY. The company posted its first net income since 2013 at RMB 20.6 million, compared to a net loss of RMB 174.5 million in the same period last year. Gross profit increased by 39.1% to RMB 307.3 million, with improved margins at 82.6%.

Operating expenses decreased by 31.6% to RMB 276.4 million, driven by cost reduction initiatives and completion of COVID-19 vaccine trials. The company received NMPA approval for a Phase III trial of its YSJA rabies vaccine's simplified regimen. For FY2025, LSB projects revenues between RMB 665-700 million (16-22% YoY growth) and Adjusted EBITDA of RMB 76-89 million.